A Global Pregnancy Registry to Assess Maternal, Fetal, and Infant Outcomes Following Exposure to YORVIPATH® (Palopegteriparatide) During Pregnancy and Breastfeeding
← catalyst calendarNCT07345494 · readout ≤ 3,452 d
Sponsored by Ascendis Pharma A/S (industry) · ASND — their whole pipeline →.
Phase
—
Status
Recruiting
Study type
Observational
Enrollment
50estimated
Sites
1
Country
United States
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2026-02-18 | actual | When the study began enrolling |
| Primary completion | Jan 2036 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | Jan 2036 | estimated | The whole study's end, after follow-up |
| First posted | 2026-01-15 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-03-02 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Hypoparathyroidism
Intervention
- Drug: Palopegteriparatide
Primary outcomes
what the primary-completion date above is the date OFThe number of fetuses as reported by HCP
measured 21 months
Pregnancy outcomes
measured 21 months
Number of congenital malformations identified in the developing fetus, neonate, or infant
measured 21 months
Descriptive statistics of adverse events (AEs), including serious adverse events (SAEs)
measured 21 months
Number of hospitalizations including reasons for hospitalization
measured 21 months
Descriptive statistics of growth and development milestones as described by the Centers for Disease Control and Prevention (CDC 2021) or other accepted standard assessment
measured 21 months
Number of signs of hypocalcemia or hypercalcemia
measured 21 months
Descriptive statistics of infant developmental deficiency (CDC 2021)
measured 21 months
Descriptive statistics of postnatal growth deficiency or failure to thrive (FTT)
measured 21 months
Descriptive statistics of neonatal and infant mortality
measured 21 months
Maternal complications of pregnancy
measured 21 months
Other maternal events of interest
measured 21 months
Permalink · ASND's whole pipeline · Catalyst calendar · Every registered study · What changed